当前位置：易推广 > 上海陶术生物科技有限公司 > 产品展示
企业档案
会员类型：会员
已获得易推广信誉 等级评定
(0 -40)基础信誉积累，可浏览访问
(41-90)良好信誉积累，可接洽商谈
(91+ )优质信誉积累，可持续信赖
易推广会员：5年
工商认证 【已认证】
最后认证时间：
注册号： 【已认证】
法人代表： 【已认证】
企业类型：生产商 【已认证】
注册资金：人民币万 【已认证】
产品数：86101
参观次数：3711307
自主品牌
已选条件
-
T10965DBPR112DBPR-112,DBPR112
DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM and 48 nM for EGFRWT and EGFRL858R/T790M, respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy.
价 格：￥电议型 号：T10965产 地：中国大陆
-
T69498DBPR112 HCl；化合物 DBPR112 HClDBPR112 HCl
DBPR112 is a potent EGFR inhibitor (IC50=487 nM) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. DBPR112), DBPR112not only displayed a potent inhibitory activity against EGFRL858R/T790M double mutations but also exhibited tenfold potency better than the third-generation inhibitor, osimertinib,against EGFR and HER2 exon 20 insertion mutations. Overall, pharmacokinetic improvement through lead-to-candidateoptimization yielded fourfold oral AUC better that afatinib along wi
价 格：￥电议型 号：T69498产 地：中国大陆
-
T10965DBPR112；化合物DBPR112DBPR112
DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM and 48 nM for EGFRWT and EGFRL858R/T790M, respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy.
价 格：￥电议型 号：T10965产 地：中国大陆
